You are here

USPTO

Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO News

Pharmaphorum

Wed, 01/17/24 - 09:38 am

At Viatris' request, US agency will review another Novo Nordisk patent on semaglutide

Fierce Pharma

Thu, 10/5/23 - 10:21 am

Pharma IP in view as new USPTO director Kathi Vidal wins Senate confirmation

Endpoints

Wed, 04/6/22 - 07:41 pm

Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet

Xconomy

Sat, 08/31/19 - 08:00 pm

Biopharma gets better chance to protect patents during inter partes review

BioCentury

Wed, 03/27/19 - 11:33 pm

inter partes review

Novartis Challenges USPTO Patent Extension Policy

Forbes

Thu, 07/8/10 - 08:54 am